The Stanford Center for Systems Biology of Cancer (CCSB) aims to discover molecular mechanisms underlying cancer progression by studying cancer as a complex biological system that is driven, in part, by impaired differentiation. Increasing evidence indicates that many cancers, like normal tissue, are composed of a hierarchy of cells at different stages of differentiation, and that the disease is maintained by a selfrenewing subpopulation. Our overarching goal is to provide a better understanding of the self-renewing properties of cancer that will enable us to identify molecular therapeutic targets and strategies to eradicate this disease, or to maintain it in a nonlethal state. Our biological projects are integrated with novel computational techniques, designed to dissect processes and causal factors underlying impaired differentiation as a driver of cancer progression in several hematologic malignancies. In order to identify mechanistic underpinnings of cancer progression, a network-based and multiscale viewpoint is mandatory. Increasingly, diseases such as cancer are recognized as resulting from disruption in the coordinated performance of a complex biological system. This systems biology viewpoint necessitates the incorporation of high throughput, high dimensional data, and development of computational methods specifically geared to its analysis. The Stanford CCSB will develop three essential and interlocking methods for a comprehensive systems analysis of cancer. First, powerful methods will be developed to infer molecular regulatory networks that drive phenotypic processes such as differentiation. Second, computational approaches will be developed that can identify and isolate underlying patterns of progression in cancer, which can then be related to underlying regulatory networks. Third, executable models will be developed so that it is possible to pose hypothetical """"""""what if questions to predict how, for example, a targeted intervention might affect the subsequent course of disease. These computational approaches will be applied to the study of differentiation in AML, Follicular Lymphoma and T-ALL. In AML, we will identify regulatory networks driving leukemic stem cells. In Follicular Lymphoma, we will analyze the relationship between BCR-sensitive and BCR-insensitive subpopulations. In T-ALL, we will study the self-renewing properties of MYC in a transgenic mouse model. Our integrative approach will enable us to ascertain differences between these hematologic malignancies, and commonalities which may generalize to other cancers. In addition, the Stanford CCSB's efforts in education and outreach aim to provide the next generation of cancer researchers with a solid foundation in ntegrative experimental and computational methods of scientific research.

Public Health Relevance

The overarching goal ofthe Stanford CCSB is to provide a better understanding ofthe differentiation and self-renewal properties of cancer that will enable us to identify molecular therapeutic targets and strategies to eradicate this disease, or at least, maintain it in a nonlethal state.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA149145-04
Application #
8448714
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (J1))
Program Officer
Gallahan, Daniel L
Project Start
2010-05-01
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
4
Fiscal Year
2013
Total Cost
$2,296,554
Indirect Cost
$1,044,784
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Sinha, Subarna; Thomas, Daniel; Chan, Steven et al. (2017) Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nat Commun 8:15580
Knowles, David A; Davis, Joe R; Edgington, Hilary et al. (2017) Allele-specific expression reveals interactions between genetic variation and environment. Nat Methods 14:699-702
O'Gorman, W E; Kong, D S; Balboni, I M et al. (2017) Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients. J Autoimmun :
Li, Yang I; van de Geijn, Bryce; Raj, Anil et al. (2016) RNA splicing is a primary link between genetic variation and disease. Science 352:600-4
Anchang, Benedict; Hart, Tom D P; Bendall, Sean C et al. (2016) Visualization and cellular hierarchy inference of single-cell data using SPADE. Nat Protoc 11:1264-79
Angst, Martin S; Fragiadakis, Gabriela K; Gaudillière, Brice et al. (2016) In Reply. Anesthesiology 124:1414-5
Aghaeepour, Nima; Chattopadhyay, Pratip; Chikina, Maria et al. (2016) A benchmark for evaluation of algorithms for identification of cellular correlates of clinical outcomes. Cytometry A 89:16-21
Gaudillière, Brice; Ganio, Edward A; Tingle, Martha et al. (2015) Implementing Mass Cytometry at the Bedside to Study the Immunological Basis of Human Diseases: Distinctive Immune Features in Patients with a History of Term or Preterm Birth. Cytometry A 87:817-29
Chapman, J; Gentles, A J; Sujoy, V et al. (2015) Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia 29:2270-3
Zhao, Xi; Rødland, Einar Andreas; Tibshirani, Robert et al. (2015) Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res 17:29

Showing the most recent 10 out of 83 publications